China's main market regulator aims to streamline the procedure for reviewing acts of economic concentration and clarifies rules for filing cases for antitrust review.
China’s State Administration for Market Regulation (SAMR) will research on and formulate antitrust guidelines for the pharmaceutical industry as well as guidelines to review horizontal business concentrations, a SAMR spokesperson said at a press conference yesterday (5 February).
A Chinese-language transcript of the press conference was published on the website of the State Council Information Office.
In its efforts to refine the antitrust and anti-unfair competition system rules, SAMR will expedite the formulation of 'Compliance Management Specification of Undertaking Fair Competition' and the revision of 'Guidelines on Anti-monopoly Compliance for Operators', the spokesperson added.
The regulator will also further scale up the efficiency of business concentration reviews by optimizing approaches and streamlining declaration documents for cases placed under its simplified review procedures.
The agency will improve the framework of delegating its merger review work, according to an article written by SAMR Antitrust Director Xu Xinjian and published on the Economic Daily yesterday.
It is also working on a technical specification for the declaration of business concentration cases for antitrust review, the Chinese-language article said.
Xu noted that SAMR aims to expedite case reviews without competition concerns and help the real estate sector with reorganization and risk resolutions.
